ADMA Biologics reports Q1 results on May 8 with short sellers quietly rebuilding positions after a sharp pullback — making the earnings print a test of whether the stock's recent momentum can hold.
Short interest has climbed meaningfully in recent weeks. It rose 8.3% over the past week to reach 9.4% of the free float — a notable level for a biotech of this size. The move reverses a broader one-month decline and marks a step-up from the mid-April lows, when SI briefly dipped below 20.5 million shares. That said, the borrow market tells a calmer story: cost to borrow is running at just 0.46%, a fraction of what a heavily contested name typically commands, and availability remains ample. This is not a setup where the lending market is under stress — short sellers are building positions cheaply, with plenty of room to add.
Options traders are leaning the other way. The put/call ratio has drifted higher toward 0.37 but remains well below its 20-day mean relative to the year's range — the 52-week high hit 0.81 — suggesting call activity continues to dominate the options flow. The z-score is just under one standard deviation above the recent average, meaning the mild uptick in put buying is barely above normal. Taken together with the stock's 9.7% one-month gain to $10.08 — despite a 4.9% pullback on the week and a 1.7% slip on Wednesday — the options market has not pivoted defensive ahead of the print.
The analyst picture has been mixed in the past few weeks. Canaccord Genuity initiated with a Buy and a $21 target on April 21. Mizuho maintained Outperform but trimmed its target from $30 to $24 earlier in April, reflecting some caution on valuation. Cantor Fitzgerald downgraded to Neutral in late March without publishing a new target. The consensus is still Buy, with a mean target implying roughly double the current price — though that gap deserves scrutiny, as the stock traded much higher in early 2026 before pulling back sharply. The forward earnings yield of roughly 10% and an EV/EBITDA multiple near 6.9x — which has compressed about 0.4 turns over the past month — suggest the market has already repriced some of the earlier optimism. On the positive side, ADMA ranks in the 84th percentile for forward EPS growth and the 91st percentile for analyst recommendation differentiation, pointing to a business still viewed as having meaningful upside by those who track it closely.
Insider activity adds a wrinkle. The CEO, Adam Grossman, and COO Kaitlin Kestenberg-Messina both sold shares in March at prices in the $15 range — well above where the stock trades today. Net insider activity over the past 90 days is technically positive at roughly $4.2 million due to small board-affiliated purchases, but the executive sells at twice the current price are the dominant signal, and they arrived ahead of what became a significant drawdown.
The Q1 report will determine whether the recent short interest rebuild reflects genuine concern about the operating trajectory — or simply opportunistic positioning into a stock that has given back nearly a third of its early-2026 highs.
See the live data behind this article on ORTEX.
Open ADMA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
